Leukotriene receptor antagonist

from Wikipedia, the free encyclopedia

Leukotrienrezeptor- antagonists (LTRA), also known as leukotriene antagonists (LRA) or anti-leukotriene agents are in the Asthma - therapy used. They form their own drug class or group of active ingredients.

commitment

Leukotriene receptor antagonists can be used in the therapy of mild to moderate asthma as an alternative to cortisone treatments , but are sometimes less effective. They are used to prevent seizures in chronic asthma. They are also used in the treatment of allergic rhinitis .

To reduce the patient's exposure to cortisone, you can supplement a cortisone treatment ( additive to corticosteroids and placebo ).

Mode of action

LTRA bind to the leukotriene receptors (LTD4 receptors) in the pulmonary system and competitively inhibit the binding of leukotrienes to their receptor in the bronchi and the activity of cysteinyl leukotrienes . Leukotrienes or cysteinyl leukotrienes are inflammatory mediators that are involved in the development of inflammation in bronchial asthma and have a bronchoconstrictive (narrowing) effect on the airways and thus worsen lung function.

Substances

The following substances can be assigned to the drug class:

In Germany in 2005 only Montekulast is approved and available. In 2005, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care with the benefit assessment of various drugs approved for asthma therapy. The use of Montekulast alone or in combination with other medications was investigated.

See also

  • Cochrane Central Register of Controlled Trials (CENTRAL)
  • Excerpta Medica Database (EMBASE)
  • Medical Literature Analysis and Retrieval System Online ( MEDLINE )

Web links

Individual evidence

  1. ↑ JP Scott, M. Peters-Golden: Antileukotriene agents for the treatment of lung disease. In: American journal of respiratory and critical care medicine. Volume 188, Number 5, September 2013, ISSN  1535-4970 , pp. 538-544, doi: 10.1164 / rccm.201301-0023PP , PMID 23822826 .
  2. ^ CH Fanta: Asthma. In: The New England Journal of Medicine . Volume 360, Number 10, March 2009, ISSN  1533-4406 , pp. 1002-1014, doi: 10.1056 / NEJMra0804579 , PMID 19264689 .
  3. ↑ Ärzteblatt - Leukotriene Receptor Antagonist: A New Option for Asthma Patients
  4. ↑ Entry on leukotriene antagonist in Flexikon , a Wiki of the DocCheck company , accessed on February 8, 2015.
  5. ↑ IQWIG report plan from 2005, accessed February 8, 2015